ReviewJournal of clinical pathology2002
Hodgkin's lymphoma: the pathologist's viewpoint.
Review in Journal of clinical pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Artificial intelligence performance in detecting lymphoma from medical imaging: a systematic review and meta-analysis.BMC medical informatics and decision making · 2024Pooled it
- Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).The Cochrane database of systematic reviews · 2018Pooled it
- Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy.BMJ clinical evidence · 2015Pooled it
- Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.The Cochrane database of systematic reviews · 2015Pooled it
- Hodgkin's lymphoma.BMJ clinical evidence · 2009Pooled it
- Clinical characteristics and short-term outcomes of pediatric lymphoma: a retrospective cohort study from a large tertiary hospital in a low- and middle-income country.Scientific reports · 2025Article
- Assessment of Treatment Outcomes and Associated Factors Among Pediatric Patients With Burkitt Lymphoma at Kenyatta National Hospital.Cancer reports (Hoboken, N.J.) · 2025Article
- Case Report: Pitfalls in bone marrow evaluation: importance of adequate bone marrow sampling.Frontiers in oncology · 2025Article
- A comparison of clinical profile and treatment outcome of Hodgkin's Lymphoma in Tanzania according to HIV status during the HAART era.BMC cancer · 2024Article
- CAR-T Cell Therapy for Classical Hodgkin Lymphoma.HemaSphere · 2023Review
- Review
- A Case of Hodgkin's Lymphoma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Forceps Biopsies.Cureus · 2023Article
- Obesity and Risk for Lymphoma: Possible Role of Leptin.International journal of molecular sciences · 2022Review
- Unusual Presentation of Hodgkin's Lymphoma in Pregnancy: A Case Report and Systematic Review of Literature.Hematology reports · 2022Article
- Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.Cancers · 2022Article
- Review
- Review
- Mitochondrial Generated Redox Stress Differently Affects the Endoplasmic Reticulum of Circulating Lymphocytes and Monocytes in Treatment-Naïve Hodgkin's Lymphoma.Antioxidants (Basel, Switzerland) · 2022Article
- Distinctive patterns of marrow involvement by classic Hodgkin lymphoma are clues for diagnosis and subtyping.Virchows Archiv : an international journal of pathology · 2022Article
- The role of immunohistochemistry in the assessment of classical Hodgkin lymphoma microenvironment.International journal of clinical and experimental pathology · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B cell derivation of the tumour in most cases, and on the relevance of Epstein-Barr virus infection and defective cytokinesis in at least a proportion of patients. The REAL/WHO classification recognises a basic distinction between lymphocyte predominance HL (LP-HL) and classic HL (CHL), reflecting the differences in clinical presentation and behaviour, morphology, phenotype, and molecular features. CHL has been classified into four subtypes: lymphocyte rich, nodular sclerosing, with mixed cellularity, and lymphocyte depleted. The borders between CHL and anaplastic large cell lymphoma have become sharper, whereas those between LP-HL and T cell rich B cell lymphoma remain ill defined. Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.